Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0020473 (
hyperlipidemia
)
15,891
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Obesity is associated with the development of some of the most prevalent diseases of modern society. The greatest risk is for diabetes mellitus where a body mass index above 35 kg/m2 increases the risk by 93-fold in women and by 42-fold in men. The risk of coronary heart disease is increased 86% by a 20% rise in weight in males, whereas in obese women the risk is increased 3.6-fold. Elevation of blood pressure,
hyperlipidaemia
and altered haemostatic factors are implicated in this high risk from coronary heart disease. Gallbladder disease is increased 2.7-fold with an enhanced cancer risk especially for colorectal cancer in males and cancer of the endometrium and biliary passages in females. Endocrine changes are associated with metabolic diseases and infertility, and respiratory problems result in sleep apnoea, hypoventilation, arrhythmias and eventual cardiac failure. Obesity is not a social
stigma
but an actual disease with a major genetic component to its aetiology and a financial cost estimated at $69 billion for the USA alone.
...
PMID:Obesity as a disease. 924 38
Atypical antipsychotic medications are associated with different adverse effects and efficacy profiles compared with conventional antipsychotics (i.e. less extrapyramidal symptoms, improved-efficacy against negative symptoms and cognitive deficits, and most often a greater ability to improve patients' quality of life). However, the atypical antipsychotics may be associated with clinically significant bodyweight gain, increasing the risk of medical comorbidity, including diabetes mellitus, hypertension, cardiovascular disease and
hyperlipidaemia
. This literature review assesses the various bodyweight gain liabilities associated with atypical antipsychotics, as well as the effects of bodyweight gain on quality of life. The issue of prevention and management of this often neglected adverse effect is also examined. Most studies reviewed indicate that clozapine and olanzapine are associated with more bodyweight gain than the other atypical antipsychotics. There are potential factors that place certain patients at greater risk for bodyweight gain, including low pretreatment body mass index, young age and being of female gender. Furthermore, bodyweight gain associated with the use of atypical antipsychotics has been reported to be associated with clinical improvement, although this has not been substantiated widely. It is unclear whether increased medical comorbidity, including diabetes mellitus, coronary artery disease and/or elevated triglyceride levels, is secondary to the bodyweight gain associated with atypical antipsychotics, or the result of the agents themselves. A patient's quality of life may be greatly affected by excessive bodyweight gain; either by increased comorbid medical illness, an increased relapse rate associated with noncompliance, or the social
stigma
associated with being obese. However, most studies reveal that treatment with atypical antipsychotic medications is associated with improved quality of life compared with that achieved with conventional antipsychotic medications. Because bodyweight is an important health risk associated with atypical antipsychotics, prevention and effective management of bodyweight are paramount in preventing comorbid medical illness, relapse and possible noncompliance.
...
PMID:Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications. 1151 Jun 24
As people living with HIV experience longer life-expectancies resulting from antiretroviral therapy, comorbid conditions are increasing, particularly metabolic disorders. There is potential for psychosocial factors such as
stigma
experiences, depression, and alcohol use to complicate both HIV infection and metabolic disorders, including diabetes mellitus and
hyperlipidemia
. While the impact of these psychosocial factors on HIV infection alone are widely studied, their role in potentially complicating HIV co-morbid metabolic conditions has received little attention. This study examined the association between HIV-related
stigma
and depression, and the potential role of alcohol use as a mediating factor in a clinical sample of patients with comorbid HIV infection and metabolic conditions. Results demonstrated that HIV
stigma
is associated with depression and this relationship is in part accounted for by alcohol use. Our results indicate that interventions aiming to improve the health of people living with HIV and co-morbid metabolic disorders should prioritize addressing alcohol use as it is related to sources of stress, such as
stigma
, and depression.
...
PMID:Psychosocial complications of HIV/AIDS-metabolic disorder comorbidities among patients in a rural area of southeastern United States. 2938 34
Natural products with high pharmacological potential and low toxicity have been considered as the novel therapeutic agents. Crocetin is an active constituent of saffron (Crocus sativus L.)
stigma
, which in its free-acid form is insoluble in water and most organic solvents. Crocetin exhibits various health-promoting properties including anti-tumor, neuroprotective effects, anti-diabetics, anti-inflammatory, anti-
hyperlipidemia
, etc. These therapeutic effects can be achieved with different mechanisms such as improvement of oxygenation in hypoxic tissues, antioxidant effects, inhibition of pro-inflammatory mediators, anti-proliferative activity and stimulation of apoptosis in cancer cells. It is also worth considering that crocetin could be tolerated without major toxicity at therapeutic dosage in experimental models. In the present review, we discuss the biosynthesis, pharmacokinetic properties of crocetin and provide a comprehensive study on the biological activities and toxicity along with the mechanism of actions and clinical trials data of crocetin.
...
PMID:A comprehensive review on biological activities and toxicology of crocetin. 3110 Mar 2